| __timestamp | Dynavax Technologies Corporation | Zoetis Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 17763000 | 1643000000 |
| Thursday, January 1, 2015 | 22180000 | 1532000000 |
| Friday, January 1, 2016 | 37257000 | 1364000000 |
| Sunday, January 1, 2017 | 27367000 | 1334000000 |
| Monday, January 1, 2018 | 64770000 | 1484000000 |
| Tuesday, January 1, 2019 | 74986000 | 1638000000 |
| Wednesday, January 1, 2020 | 79256000 | 1726000000 |
| Friday, January 1, 2021 | 100156000 | 2001000000 |
| Saturday, January 1, 2022 | 131408000 | 2009000000 |
| Sunday, January 1, 2023 | 152946000 | 2151000000 |
| Monday, January 1, 2024 | 2318000000 |
Unlocking the unknown
In the competitive landscape of the pharmaceutical industry, understanding operational efficiency is crucial. This analysis compares the Selling, General, and Administrative (SG&A) expenses of Zoetis Inc. and Dynavax Technologies Corporation from 2014 to 2023.
Zoetis Inc., a leader in animal health, has consistently maintained high SG&A expenses, peaking at approximately $2.15 billion in 2023. Despite the high costs, Zoetis's strategic investments in marketing and administration have supported its robust market position.
Dynavax Technologies, a smaller player, has seen its SG&A expenses grow by over 750% from 2014 to 2023, reflecting its aggressive expansion strategy. This growth underscores Dynavax's commitment to scaling its operations and increasing its market footprint.
Both companies illustrate different strategies in managing SG&A expenses, offering valuable insights into their operational priorities.
Selling, General, and Administrative Costs: Johnson & Johnson vs Dynavax Technologies Corporation
Breaking Down SG&A Expenses: Merck & Co., Inc. vs Dynavax Technologies Corporation
Who Optimizes SG&A Costs Better? Gilead Sciences, Inc. or Dynavax Technologies Corporation
Breaking Down SG&A Expenses: Zoetis Inc. vs Bio-Techne Corporation
Breaking Down SG&A Expenses: Zoetis Inc. vs BioCryst Pharmaceuticals, Inc.
Operational Costs Compared: SG&A Analysis of United Therapeutics Corporation and Dynavax Technologies Corporation
Selling, General, and Administrative Costs: CRISPR Therapeutics AG vs Dynavax Technologies Corporation
SG&A Efficiency Analysis: Comparing MorphoSys AG and Dynavax Technologies Corporation
Selling, General, and Administrative Costs: ImmunityBio, Inc. vs Dynavax Technologies Corporation
Soleno Therapeutics, Inc. vs Dynavax Technologies Corporation: SG&A Expense Trends
Operational Costs Compared: SG&A Analysis of Dynavax Technologies Corporation and Travere Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for Dynavax Technologies Corporation and Celldex Therapeutics, Inc.